There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > DDR2


DDR2 Molecule Information

Name:Discoidin domain-containing receptor 2
Target Synonym:CD167b,NTRKR3,CD167 Antigen-Like Family Member B,Discoidin Domain Receptor 2,Hydroxyaryl-Protein Kinase,CD167b Antigen,Discoidin Domain-Containing Receptor 2,Tyrosine-Protein Kinase TYRO10,Discoidin Domain-Containing Receptor Tyrosine Kinase 2,TKT,Discoid
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

DDR2 Molecule Synonym Name


DDR2 Molecule Background

Discoidin domain-containing receptor 2 (DDR2) is also known as CD167 antigen-like family member B (CD167b), Discoidin domain-containing receptor tyrosine kinase 2, Neurotrophic tyrosine kinase, receptor-related 3(NTRKR3), Tyrosine-protein kinase TYRO10, Tyrosine kinase that functions as cell surface receptor for fibrillar collagen and regulates cell differentiation, remodeling of the extracellular matrix, cell migration and cell proliferation. DDR2 is required for normal bone development. DDR2 regulates osteoblast differentiation and chondrocyte maturation via a signaling pathway that involves MAP kinases and leads to the activation of the transcription factor RUNX2. DDR2 regulates remodeling of the extracellular matrix by up-regulation of the collagenases MMP1, MMP2 and MMP13, and thereby facilitates cell migration and tumor cell invasion. DDR2 promotes fibroblast migration and proliferation, and thereby contributes to cutaneous wound healing.

DDR2 References

DDR2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Regorafenib Monohydrate BAY-73-4506; DAST Approved Bayer Ag Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors s:15:"Bayer Pharma Ag"; 2012-09-27 Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details

DDR2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CG-806 CG-806; CG-026806 Phase 2 Clinical Crystalgenomics Inc, Aptose Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.